Semaglutide and tirzepatide are both injectable medications used for type 2 diabetes and weight loss, but they differ in a fundamental way: semaglutide activates one gut hormone receptor, while tirzepatide activates two. That distinction drives meaningful differences in how much weight people lose, how well blood sugar drops, and which brand names you’ll see on a prescription.
How Each Drug Works
Semaglutide mimics a natural hormone called GLP-1 that your gut releases after eating. By binding to GLP-1 receptors, it triggers insulin release when blood sugar is high, tells the liver to produce less sugar, and slows the rate food leaves your stomach. That slower digestion keeps you feeling full longer and reduces appetite.
Tirzepatide does all of that, plus it also activates a second receptor called GIP. GIP is another incretin hormone your body produces after meals, and it amplifies several of the same effects: better insulin response, reduced appetite, and greater energy expenditure. This dual mechanism is the core reason tirzepatide tends to outperform semaglutide in clinical trials. Think of semaglutide as pulling one lever and tirzepatide as pulling two at the same time.
Weight Loss Results
Both drugs produce significant weight loss, but tirzepatide consistently delivers more. In the SURMOUNT-1 trial, adults with obesity who took tirzepatide lost between 16% and 22.5% of their starting body weight over 72 weeks, depending on the dose. At the highest dose (15 mg), the average was about 22.5%, which for a 220-pound person translates to roughly 50 pounds.
Semaglutide’s landmark weight-loss trial, STEP 1, showed an average loss of about 15% of body weight at 2.4 mg over 68 weeks. That’s still substantial and far beyond what older weight-loss medications achieved, but it’s noticeably less than tirzepatide’s top dose.
The only head-to-head trial, SURPASS-2, confirmed the gap. All three tirzepatide doses produced greater weight reduction than semaglutide 1 mg in people with type 2 diabetes. It’s worth noting that trial compared tirzepatide against the diabetes dose of semaglutide (1 mg), not the higher weight-management dose (2.4 mg), so the real-world difference at maximum doses may be somewhat narrower.
Blood Sugar Control
For people with type 2 diabetes, both medications lower A1C effectively, but tirzepatide again has an edge. In the SURPASS trials, up to 92% of participants on tirzepatide reached an A1C below 7%, which is the standard target for most people with diabetes. Even more striking, up to 52% hit an A1C below 5.7%, a level normally seen in people without diabetes at all.
In the direct comparison (SURPASS-2), all three tirzepatide doses produced greater A1C reductions than semaglutide 1 mg. Semaglutide is still a highly effective diabetes medication, but tirzepatide’s dual-receptor activity appears to give it a consistent advantage for blood sugar control.
Brand Names and FDA Approvals
Each drug is sold under two brand names, one approved for diabetes and one for weight management:
- Semaglutide: Ozempic (type 2 diabetes) and Wegovy (chronic weight management)
- Tirzepatide: Mounjaro (type 2 diabetes) and Zepbound (chronic weight management)
The weight-management versions, Wegovy and Zepbound, are approved for adults with a BMI of 30 or higher, or 27 or higher if they also have a weight-related condition like high blood pressure, high cholesterol, type 2 diabetes, sleep apnea, or cardiovascular disease. The formulations are identical within each drug. The difference is which condition your doctor prescribes it for, which affects insurance coverage.
Heart Health
Semaglutide has a proven cardiovascular benefit that tirzepatide hasn’t matched yet. In the SELECT trial, semaglutide reduced major cardiovascular events (heart attacks, strokes, and cardiovascular death) by 20% in people with obesity and established heart disease who did not have diabetes. That’s a meaningful result and one reason some doctors prefer semaglutide for patients with known heart problems.
Tirzepatide does not yet have a completed large-scale cardiovascular outcomes trial. Early data look promising, but until those results are published, semaglutide holds a unique advantage for patients where heart protection is a priority.
Dosing and Titration
Both drugs are once-weekly injections given under the skin, typically in the abdomen, thigh, or upper arm. Both follow a gradual dose-increase schedule to minimize side effects.
Semaglutide starts at 0.25 mg per week. The dose increases by 0.25 mg every four weeks until reaching the target, which is 1 mg for diabetes (Ozempic) or 2.4 mg for weight management (Wegovy). Reaching the full weight-loss dose takes about 16 to 20 weeks.
Tirzepatide starts at 2.5 mg per week and increases by 2.5 mg every four weeks, up to a maximum of 15 mg. The numbers are larger, but that doesn’t mean the drug is “stronger” milligram for milligram. They’re simply measured on different scales. Your prescriber will adjust the target dose based on how you respond and what you can tolerate.
Side Effects and Tolerability
The side effect profiles are very similar because both drugs slow digestion and act on overlapping pathways. The most common complaints are nausea, vomiting, diarrhea, and constipation, especially during the dose-increase phase. These tend to improve over several weeks as your body adjusts.
In the SURPASS-2 head-to-head trial, tirzepatide led to slightly higher discontinuation rates due to side effects: 6% to 8.5% of people on tirzepatide stopped the medication because of adverse events, compared with 4.1% on semaglutide 1 mg. This suggests tirzepatide may be a bit harder to tolerate for some people, particularly at higher doses. The gradual titration schedule exists specifically to ease into the medication and reduce these issues.
Choosing Between Them
If maximum weight loss or blood sugar reduction is the primary goal, tirzepatide’s dual-receptor approach gives it a measurable advantage in clinical trials. If cardiovascular protection matters most, semaglutide is the only one with proven heart-outcome data so far. Tolerability, insurance formulary placement, and out-of-pocket cost often end up being the deciding factors in practice, since both drugs carry high list prices and coverage varies widely by plan.
For many people, either medication represents a major step forward compared to older options. The “best” choice depends on your specific health profile, what your insurance covers, and how your body responds during the titration period.